News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...
Daily Voice on MSN19h
Plainsboro-Based Wegovy Provider Ends Hims & Hers Deal Over Knockoff Weight-Loss Drug SalesNovo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...
Hims & Hers Health stock plunged after Novo Nordisk (NYSE: NVO) cut ties over concerns about its handling of Wegovy ...
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback